Small molecule inhibitors such as axitinib [46], imatinib [47], and apatinib [48] target VEGF receptors (VEGFRs) on endothelial cells, while sorafenib [49] inhibits VEGFRs and RAF/MEK/ERK pathways, serving dual roles as anti‐angiogenic and signaling pathway inhibitors in melanoma therapy. This evidence concerns the gene MAP2K7 and melanoma.